Bioanalysis
Altasciences Continues to Expand North American Bioanalytical Footprint
Laval, Québec, August 11, 2026 — Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations.
The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027.
These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience.
Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studies and higher sample volumes while incorporating state-of-the-art instrumentation and advanced laboratory automation for pharmacokinetic and pharmacodynamic assay method development, validation, and sample analysis across the clinical phases drug development. The additional capacity and streamlined workflows will reduce turnaround times, enabling sponsors to obtain critical bioanalytical data faster, make informed development decisions sooner, and keep clinical programs moving forward.
"Our clients are bringing increasingly complex molecules into development, and that is driving unprecedented demand for sophisticated bioanalytical support," said Lynne Le Sauteur, Vice President, Laboratory Sciences, Altasciences. "We're investing ahead of that demand by expanding capacity where sponsors need it most and deploying state-of-the-art instrumentation and automation that enhances speed without compromising quality.”
The expansion project strengthens Altasciences’ broader North American bioanalytical network, which includes established laboratories in Greater Montréal (Quebec), Seattle (Washington), and Columbia (Missouri). Together, these locations provide sponsors with bioanalytical expertise and capacity across the drug development continuum, supporting programs from nonclinical research through late-stage clinical development while helping de-risk global trials through built-in flexibility, scalability, and business continuity.
“Because every Altasciences laboratory is built on the same harmonized scientific platform, sponsors gain the flexibility to scale programs across locations while receiving the consistent, high-quality data they rely on to make critical development decisions," stated Lynne Le Sauteur.
All Altasciences laboratories are designed and built from the ground up using the same validated quality systems, scientific workflows, instrumentation platforms, and operational processes. This network-wide harmonization enables sponsors to leverage capacity across locations, transition work seamlessly between laboratories, and maintain complete confidence in the integrity and consistency of their bioanalytical data.
"This investment is about far more than expanding laboratory space," said Robert Sabelli, Co-Chief Operating Officer, Altasciences. "We're building one of the industry's most integrated and scalable bioanalytical networks. As clinical programs become larger, more complex, and increasingly global, sponsors need a partner that can rapidly scale capacity while delivering consistent scientific excellence across every location. That's exactly what we're delivering."
These investments reinforce Altasciences’ integrated drug development platform and underscore the company's commitment to investing in people, facilities, technologies, automation, and the scientific expertise needed to help clients accelerate drug development with confidence.
About Altasciences
Altasciences is a drug development organization dedicated to safely accelerating early-phase development for biotech, biopharmaceutical, and pharmaceutical companies. By combining the scale and expertise of a large CRO/CDMO with the flexibility and personalized approach of a mid-size partner, Altasciences delivers unified solutions across nonclinical, clinical, bioanalytical, and formulation and manufacturing services. Through intentional integration and true collaboration, the company removes barriers from lead candidate selection to clinical proof-of-concept—helping sponsors save time, reduce complexity, and make confident, data-driven decisions that enable earlier returns on investment. Guided by over 30 years of experience and a commitment to quality, integrity, and partnership, Altasciences enables clients to reach critical milestones faster and with greater confidence. To learn more about Altasciences, visit altasciences.com.
Julie-Ann Cabana
Altasciences
media@altasciences.com
Altasciences Completes Expansion of Research and Development Laboratory in Harleysville, Pennsylvania
Laval, Québec, August 4, 2026 — Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space.
The expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scientific disciplines.
“With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities to clients earlier in the drug development journey,” said Anuji Abraham, Senior Director, Pharmaceutical Development, CDMO Services, Altasciences. “This enhances continuity across nonclinical and clinical programs, helping clients navigate key development milestones more efficiently and effectively.”
The enhanced laboratory supports phase-appropriate, target product profile (TPP)-driven formulation screening, tailored to both therapeutic areas and routes of administration while remaining agnostic to both. Capabilities include formulation development for small molecules, peptides, and complex modalities, as well as non-GLP and GLP toxicology samples for nonclinical studies.
Advanced screening models and Integrated analytical testing support nonclinical and clinical readiness, in addition to real-time formulation decisions. By operating in a non-GLP R&D environment, clients will gain flexibility to design and optimize their products before transitioning into regulated studies.
“This expansion is not just about building additional space,” said Robert Sabelli, Co-Chief Operating Officer, Altasciences. “By continuing to invest in our team, we are growing our scientific talent and connecting our capabilities earlier in the development cycle to better support our clients—and ultimately, the patients they serve.”
About Altasciences
Altasciences is a drug development organization dedicated to safely accelerating early-phase development for biotech, biopharmaceutical, and pharmaceutical companies. By combining the scale and expertise of a large CRO/CDMO with the flexibility and personalized approach of a mid-size partner, Altasciences delivers unified solutions across nonclinical, clinical, bioanalytical, and formulation and manufacturing services. Through intentional integration and true collaboration, the company removes barriers from lead candidate selection to clinical proof-of-concept—helping sponsors save time, reduce complexity, and make confident, data-driven decisions that enable earlier returns on investment. Guided by over 30 years of experience and a commitment to quality, integrity, and partnership, Altasciences enables clients to reach critical milestones faster and with greater confidence. To learn more about Altasciences, visit altasciences.com.
Julie-Ann Cabana
Altasciences
media@altasciences.com
Flow Cytometry Bioanalysis for Immunomodulation Studies
Beyond the Cycle: The New Era of PCR in Translational Research
For years, Polymerase Chain Reaction (PCR) has been a foundational laboratory technique, valued for its reliability and versatility. But as we move deeper into the era of ultra-personalized genetic medicine, its role has evolved significantly.
Regulatory Pathways by Region―A Comparative Table
The Year in Review 2025
Biodistribution and Transcript Quantification in Mouse Tissues Using ddPCR
Microsampling with Impact-Assisted Extraction for Hematocrit-Free Assays
Volumetric Microsampling with Hybridization LC–MS/MS for Antisense Oligonucleotide Quantitation
Highlights From the International Society for the Advancement of Cytometry Conference 2025 by Martin Turcotte
CYTO 2025, the 38th annual Congress of the International Society for the Advancement of Cytometry, is the premier, inclusive, and international conference on the many facets of cytometry science and engineering.